Modulation of multidrug resistance P-glycoprotein activity by antiemetic compounds in human doxorubicin-resistant sarcoma cells (MES-SA/Dx-5): Implications on cancer therapy

Journal of Biological Regulators and Homeostatic Agents

Volumn 27, Issue 4, 2013, Pages 1029-1037

  Angelini, Antonio ^a   Conti, P ^a   Ciofani, G ^a   Cuccurullo, F ^a   Di Ilio, C ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

6 Gingerol; Antiemetics; Dimenhydrinate; Doxorubicin; GSH; MDR; MES SA Dx5; Ondansentron; P glycoprotein; ROS

Indexed keywords

(6) GINGEROL; DIMENHYDRINATE; DOXORUBICIN; GLUTATHIONE; MULTIDRUG RESISTANCE PROTEIN; ONDANSETRON; REACTIVE OXYGEN METABOLITE; VERAPAMIL;

ANTIEMETIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER THERAPY; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MTT ASSAY; PLANT ROOT; PROTEIN EXPRESSION; SARCOMA CELL; UTERUS SARCOMA;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIEMETICS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; HUMANS; P-GLYCOPROTEIN; REACTIVE OXYGEN SPECIES; SARCOMA;

EID: 84893336206     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ling V. Multidrug resistance: molecular mechanism and clinical relevance. Cancer Chemother Pharmacol 1997; 40:3-8.
2. Pastan I, Gottesman MM. Multiple-drug resistance in human cancer. N Engl J Med 1987; 316:1388-93. (Pubitemid 17079683)
3. Nooter K, and Stoter G. Molecular mechanism of multidrug resistance in cancer chemotherapy. Pathol Res Pract 1996; 192:768-80. (Pubitemid 26302251)
4. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53:615-27. (Pubitemid 34177898)
5. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58. (Pubitemid 37328807)
6. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80:2735-9.
7. Endicott JA, Ling VZ: The biochemistry of P-glycoprotein mediated multidrug resistance. Annu Rev Biochem 1989; 58:137-71. (Pubitemid 19172967)
8. Higgins CF: ABC transporters: from microorganism to man. Annu Rev Cell Biol 1992; 8:67-113.
9. Sauna ZE, Smith MM, Muller M, Kerr KM, Ambudkar SV: The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 2001; 33:481-91. (Pubitemid 34052574)
10. Trambas CM, Muller HK, Woods GM. P-glycoprotein mediated multidrug resistance and its implications for pathology. Pathology 1997; 29:122-30. (Pubitemid 27296457)
11. Davidson K, Conte S, Mader S, Miller WH. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 2003; 17:931-40. (Pubitemid 36626322)
12. Batist G, Schecter RL, Alaoui-Jamali MA. The glutathione system and drug resistance. In: Principles of antineoplastic drug development and pharmacology. Shilsky RL, Milano GD, Ratain M.J. Eds New York Dekker; 1996; 503.
13. Ruiz-Gomez MJ, Souviron A, Martinez-Morillo M, Gil LJ. P-glycoprotein, glutathione and glutathione S-transferase increase in a colon carcinoma cell line by colchicine. Physiol Biochem 2000; 56:307-12. (Pubitemid 32216811)
14. Batist G, Schecter R, Woo A, Greene D, Lehnert S. Glutathione depletion in human and in rat multidrug resistant breast cancer cell lines. Biochem Pharmacol 1991;41:631-5.
15. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11:265-83.
16. Borowski E, Bontemps-Gracz MM, Piwkowska A. Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells. Acta Biochim Pol 2005; 52:609-27. (Pubitemid 41571706)
17. Didier A, Wenger J, Loor F. Decreased uptake of cyclosporine A by P-glycoprotein (Pgp) expressing CEM leukemic cells and restoration of normal retention by Pgp blockers. Anticancer Drugs 1995; 6:669-80.
18. Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006; 7(7):861-79.
19. Angelini A, Di Ilio, Castellani ML, Conti P, Cuccurullo F. Modulation of multidrug resistance P-glycoprotein activity by flavonoids and honokiol in human doxorubicin-resistant sarcoma cells (MES-SA/Dx5): implications for natural sedative sas chemosensitizing agents in cancer therapy. J Biol Regul Homeost Agents 2010; 24(2):197-205.
20. Angelini A, Di Pietro R, Centurione L, Castellani ML, Conti P, Porreca E, Cuccurullo F, Di Ilio C. Inhibition of P-glycoprotein-mediated transport by S-adenosylmethionine and Cynarin in multidrug-resistant human uterine sarcoma MES-SA/Dx5 cells. J Biol Regul Homeost Agents 2012; 26(3):495-504.
21. Lajolo PP, del Giglio A. Skipping day 2 antiemetic medications may improve chemotherapy induced delayed nausea and vomiting control: results of two pilot phase II trials. Support Care Cancer 2007; 15:343-346.
22. Luisi FA, Petrilli AS, Tanaka C, Caran EM. Contribution to the treatment of nausea and emesis induced by chemotherapy in children and adolescents with osteosarcoma. Sao Paulo Med J 2006; 124 (2): 61-5.
23. Haniadka R, Popouri S, Palatty PL, Arora R, Baliga MS. Medicinal plants as antiemetics in the treatment of cancer: a review. Integr Cancer Ther 2012; 11(1):18-28.
24. Scavone JM, Luna BG, Harmatz JS, von Moltke L, Greenblatt DJ. Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. Biopharmaceutics & Drug Disposition 1990; 11(3):185-9. (Pubitemid 20271426)
25. Wesolowska O, Paprocka M, Koziak J, Motohashi N, Dus D, Michalak K. Human sarcoma cell lines MES-SA and MES-SA/Dx5 as a model for multidrug resistance modulators screening. Anticancer Res 2005; 25:383-389. (Pubitemid 40470134)
26. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 2005; 25:383-389.
27. Mosmann T. J. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J. Immunol. Methods 1983; 65:55-63.
28. Ellman GC. Tissue sulfhydrylic groups. Arch Biochem Biophys 1959, 82: 70-77.
29. Jakubowski W, Bartosz G: 2,7-dichlorofluorescein oxidation and reactive oxygen species: what does it measure. Cell Biol Int 2000; 24: 757-760.
30. Zick SM, Ruffin MT, Djuric Z, Normolle D, Brenner DE. Quantification of 6-, 8- and 10- Gingerols and 6-Shogaol in human plasma by high-performance liquid chromatography with electrochemical detection. Int. J. Biomed Sci 2010; 6(3): 233-240.